文献速递血栓与止血贫血与红细胞疾病

血栓性血小板减少性紫癜患者静脉血栓栓塞的时点患病率与特征

Describing the point prevalence and characteristics of venous thromboembolism in patients with thrombotic thrombocytopenic purpura.
PubMed 文献 · J Thromb Haemost · 2020-08-27

该单中心回顾性研究纳入77例TTP患者共123次发作,发现14例(18%)发生16次VTE,其中6例肺栓塞、6例深静脉血栓、4例浅静脉血栓。除浅静脉血栓外VTE时点患病率为14%,所有VTE均发生于急性TTP住院期间,多数未接受药物性血栓预防。

要点

  • TTP患者VTE时点患病率为14%(排除浅静脉血栓),所有事件均发生于急性TTP住院期间。
  • 多数VTE(9/16)发生于未接受药物性血栓预防的患者,提示需早期实施VTE预防。
  • VTE发生时血小板和LDH已基本恢复正常,提示TTP相关VTE可能发生在血液学恢复后。

核心结论

  • TTP患者可能存在VTE风险,且VTE多发生于血液学恢复后,与动脉血栓事件病理生理可能不同。
  • 研究提示需在TTP住院患者中更早实施VTE血栓预防。

研究设计与样本

  • 单中心回顾性病历审查,纳入10年间77例连续TTP患者共123次TTP发作,采用描述性统计。

主要发现

  • 14例患者(18%)发生16次VTE,包括6例肺栓塞、6例深静脉血栓、4例浅静脉血栓。
  • 排除浅静脉血栓后VTE时点患病率为14%。
  • 所有VTE均为急性且与急性TTP住院相关;诊断VTE时血小板中位数175×10^9 U/L(IQR 130.75–250),LDH中位数232 U/L(IQR 178.75–263.5)。
  • 16次VTE中9次发生于未接受药物性血栓预防时;除1例外均接受抗凝治疗,无致死性或大面积VTE。
  • 8例在VTE诊断时同时接受血浆置换的患者中,6例使用溶剂去垢剂血浆(SDP)进行置换。

临床怎么用

  • 对住院TTP患者应早期评估并实施VTE血栓预防,尤其在高危时段。
  • 即使在血小板和LDH恢复后仍需警惕VTE发生。
  • 使用SDP进行血浆置换时需关注潜在促血栓效应。

局限性

  • 单中心回顾性设计,样本量有限(77例患者、123次发作),结果需外部验证。
  • SDP促血栓效应仅为可能性推测,未做因果推断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Arterial thromboembolic events are relatively common and well-described in patients with thrombotic thrombocytopenic purpura (TTP). However, the literature describing venous thromboembolism (VTE) in TTP is scarce. METHODS: Single-institution retrospective chart review was conducted in TTP patients over a 10-year period to describe the point prevalence of VTE. Data were analyzed using descriptive statistics. RESULTS: We identified 77 consecutive patients with 123 episodes of TTP. Of these patients, 14 (18%) experienced 16 VTEs (6 pulmonary embolisms, 6 deep vein thromboses, 4 superficial vein thromboses [SVT]). Excluding SVT, the point prevalence of VTE was 14%. All were acute and associated with admission for acute TTP. All patients were treated with plasma exchange (PLEX); 6/8 patients on concurrent PLEX at VTE diagnosis were exchanged with solvent-detergent plasma (SDP). Platelet and lactate dehydrogenase levels at time of VTE diagnosis had largely normalized from presentation values (median 175 × 109 U/L [interquartile range 130.75, 250] and 232 U/L [interquartile range 178.75, 263.5], respectively). Most VTEs (9/16) occurred while patients were not on pharmacologic thromboprophylaxis. All but one VTE was treated with anticoagulation. No VTEs were fatal or massive. CONCLUSIONS: Our data provide additional evidence that TTP patients may be at risk for VTE. It is possible that SDP exerted a prothrombotic effect. TTP-associated VTEs may be pathophysiologically distinct from arterial thromboses because they occur following hematological recovery. VTE thromboprophylaxis was not commonly used. Our findings suggest the need to implement VTE thromboprophylaxis earlier in hospitalized patients with TTP.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Tse B, Lim G, Sholzberg M, et al. Describing the point prevalence and characteristics of venous thromboembolism in patients with thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020. PMID: 33448602. doi:10.1111/jth.15027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。